PNT News and Press, POINT Biopharma Global Inc. From 03/15/22

Learn what “PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied” means in the context of radiopharmaceuticals Register online at https://hub.pointbiopharma.com/dosimetry INDIANAPOLIS, March 15, 2022 (G...

Dosimetry data demonstrated PNT2002 has a ​ favorable and safe dosimetry profile in the patient population and dose regimen being studied Red marrow dosimetry was well below critical thresholds, enabling a potential opportunity for combination therapy INDIAN...

INDIANAPOLIS, Feb. 17, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced that the Companyȁ...

Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) inhibitor program, planned for summer 2022 Initiated IND-enabling studies for next-generation actinium-225 radiolabeled PSMA targeted program, PNT2001, to su...

Recording the biggest intraday gain since Dember, POINT Biopharma (PNT +12.4%) has neared a two-month high after the company shared its latest updates on production and late-stage clinical trials. The company said that its Indianapolis manufacturing facility was launched in October 2021, and ...

Company’s radiopharmaceutical manufacturing facility now operational, supplying doses for the Phase 3 SPLASH trial – view the facility at manufacturing.pointbiopharma.com Will receive actinium-225 in 2022 from the US Department of Energy Isotope Program to ...

POINT Biopharma (PNT +9.9%) has recorded the biggest intraday gain since early September after the company announced several changes to its senior leadership team. Justyna Kelly, Vice President, Medical Isotope Development and Operations has been promoted to the role of Chief Operating Office...

Justyna Kelly promoted to COO, Dr. Robin Hallett promoted to VP, Discovery and Translational Sciences, Dr. Sherin Al-Safadi to join as VP Medical Affairs, and Michael Gottlieb (CCO) to depart the Company to pursue other opportunities Jonathan Ross Goodman elected Lead Independen...

POINT Biopharma Global (NASDAQ:PNT) and Studiecentrum voor Kernenergie/Centre d’Etude de l’Energie Nucléaire, also known as the Belgian Nuclear Research Center (“SCK CEN”), announce a technology license agreement for Lu-177 purification technology to accelerat...

INDIANAPOLIS and MOL, Belgium , Nov. 24, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, and Studiecentrum voor Kernenergie/Centre d’Etude de l’Energ...